Recently, the Market Supervision Administration of Haidian District, Beijing, has reviewed and announced the special projects for the cultivation and layout of high-value patents for small and medium-sized enterprises in Haidian District in 2024, the special matching awards for patent prizes for small and medium-sized enterprises in Haidian District in 2024, and the special subsidy for intellectual property securitization financing costs in Haidian District in 2024. After relevant procedures, a final list of supported projects has been formed.METiS TechBio Receives Support for the "2024 High-Value Patent Cultivation and Layout Special Project for Small and Medium Enterprises in Haidian District"
To date, METiS TechBio has filed over 130 patent applications and obtained more than 30 authorized patents. These cover AI-driven design of drug delivery systems, AI-assisted optimization of complex formulations, and AI-driven nucleic acid drug development, spanning areas such as anti-cancer, obesity, degenerative diseases, and autoimmune disorders. In addition, the company owns multiple software copyrights and registered trademarks, continuously building an extensive and deep intellectual property moat.This special support is a high recognition of METiS TechBio's independent innovation and patent value transformation capabilities, and will further help us accelerate technology implementation, promoting the clinical transformation of more high-value achievements.METiS TechBio (METiS Pharmaceuticals) was founded in 2020 as an innovative biotechnology company driven by artificial intelligence (AI) for drug delivery and drug discovery.METiS TechBio aims to drive the development of innovative drugs more efficiently and precisely by integrating cutting-edge technologies such as novel AI, machine learning, and quantitative simulations with drug discovery. This includes designing effective innovative delivery materials, selecting drug candidates, formulating designs, developing "programmable nucleic acid drugs," and designing nucleic acid delivery systems. These efforts aim to bring revolutionary medicines to patients worldwide, addressing unmet clinical needs.METiS TechBio was founded by Chen Hongmin, an academician of the US National Academy of Engineering, andMITFounded and led by top scientists Dr. Lai Caida and Dr. Wang Wenshou. In recent years, AIGC technology has accelerated intelligent transformation across various industries. In the pharmaceutical industry, METiS TechBio is driving change in drug delivery (LNP) and nucleic acid drugs (RNA) through AI technology.
Learn More About METiS TechBio
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)